Search Results
Apr 21, 2026, 08:46 ET DataOps.live Named Data Breakthrough Awards' DataOps Platform of the Year
organizations to operationalize data for trusted AI at enterprise scale. Built for Snowflake and modern data cloud ecosystems, the Platform automates testing, CI/CD, and governance to deliver production-grade data products at enterprise scale. DataOps.live eliminates manual, brittle processes that slow AI initiatives
More news about: DataOps.live
Apr 21, 2026, 08:00 ET Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA® (infliximab-dyyb)Findings emphasize clinical decision-making in long-term
More news about: Celltrion
Apr 21, 2026, 06:00 ET PEOPLES BANCORP INC. ANNOUNCES RESULTS FOR THE FIRST QUARTER 2026
8.79 %Return on average tangible equity (c)(d)14.90 %
More news about: Peoples Bancorp Inc.
Apr 21, 2026, 01:25 ET Sparrow to Demonstrate AI-Driven Security and SBOM Management at Black Hat Asia 2026
Application Security Testing (DAST), and Software Composition Analysis (SCA) into a single, cohesive environment. The platform connects seamlessly with CI/CD pipelines and development environments, enabling continuous security across the entire software development lifecycle. Its AI-powered vulnerability prioritization
More news about: Sparrow Co., Ltd.
Apr 21, 2026, 01:25 ET Sparrow to Demonstrate AI-Driven Security and SBOM Management at Black Hat Asia 2026
Application Security Testing (DAST), and Software Composition Analysis (SCA) into a single, cohesive environment. The platform connects seamlessly with CI/CD pipelines and development environments, enabling continuous security across the entire software development lifecycle. Its AI-powered vulnerability prioritization
More news about: Sparrow Co., Ltd.
Apr 20, 2026, 13:15 ET Verismo Therapeutics' Initial Clinical Data from STAR-101 Phase 1 Trial of SynKIR™-110 KIR-CAR Presented at AACR 2026 Plenary Session
(KIR) and DAP12 to split the target binding and T cell activation signals provides a novel paired immune-receptor activation that is independent from CD3 signaling, and works independent of co-stimulation. KIR-CAR enables sustained cell receptor expression in T cells, and induces deeper, more durable
More news about: Verismo Therapeutics
Apr 20, 2026, 10:51 ET St. David's South Austin Medical Center first in world to enroll patient in clinical trial evaluating a next-generation treatment for aggressive large B-cell lymphoma
treated. This trial specifically evaluates the efficacy and safety of ronde-cel versus the investigator's choice of approved CD19 CAR T-cell therapies designed to target the CD19 protein on cancerous B-cells in patients with aggressive large B-cell lymphoma receiving treatment in the second-line setting.
More news about: St. David's South Austin Medical Center
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
limitation of conventional CD19/CD20 monoclonal antibodies and existing TCEs in these indications.The results come amid growing momentum in the TCE field. Since late 2024, the sector has seen increased deal activity, including Merck's USD 1.3 billion acquisition of CN201 (CD3/CD19) and GSK's USD 300 million
More news about: Abogen
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
limitation of conventional CD19/CD20 monoclonal antibodies and existing TCEs in these indications.The results come amid growing momentum in the TCE field. Since late 2024, the sector has seen increased deal activity, including Merck's USD 1.3 billion acquisition of CN201 (CD3/CD19) and GSK's USD 300 million
More news about: Abogen
Apr 20, 2026, 09:00 ET Verdent: The World's First AI Engineering Team for Builders
one-off snippets, Verdent is designed to carry software work across the full path from intent to outcome. Describe what you want to build—a dashboard, a CI/CD pipeline, a feature rollout, or an internal tool—and Verdent gets to work. It breaks the goal into tasks, selects the right tools, writes and modifies
More news about: Verdent AI
Apr 20, 2026, 08:05 ET Accord BioPharma's IMULDOSA® (ustekinumab-srlf) Now Preferred Under Cigna Healthcare Commercial Plans
who are candidates for phototherapy or systemic therapyactive psoriatic arthritis (PsA)moderately to severely active Crohn's disease (CD)moderately to severely active ulcerative colitisPediatric patients 6 years and older with:moderate
More news about: Accord BioPharma
Apr 20, 2026, 07:30 ET TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
worldwide development and commercialization rights to felzartamab, consolidating global rights under one ownerAdvancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions – in the Greater China Region presents an important
More news about: TJ Biopharma
Apr 20, 2026, 07:00 ET Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
cytotoxic markers were analyzed using flow cytometry.In vitro studies evaluated NK cell cytotoxic function following Quar Oze treatment by measuring CD107a degranulation and CellTrace Violet–based proliferation. In the therapeutic treatment group, 67% of Tusc2 KO mice and 33% of Tusc2 WT mice achieved
More news about: Genprex, Inc.
Apr 20, 2026, 04:17 ET Fapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline
challenges associated with traditional multi-specific antibodies. This technology is represented in the company's expanding CD3/TCR VHHs, including FPE024, a potential best-in-class CD19xBCMAxCD3 tri-specific T-cell engager for autoimmune indications, and FPE021, a potential best-in-class CDH17-targeting
More news about: Fapon Biopharma
Apr 18, 2026, 04:31 ET Tech TAILG. Leading Globally: TAILG Showcases at the 139th Canton Fair
automotive-grade fast-charging technology and an integrated "vehicle + charging station" solution. It offers up to 150 km range and is equipped with a 50,000cd intelligent headlight and a TCS traction control system, delivering balanced performance in power, safety, and lighting.
More news about: TAILG
Apr 17, 2026, 20:30 ET Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102
More news about: Antengene Corporation Limited
Apr 17, 2026, 20:29 ET Banistmo Announces Expiration and Results of its Consent Solicitation relating to its 4.250% Senior Notes due 2027
CUSIP Nos. 06034L AB6 / P15383 CD5PANAMA CITY, April 17, 2026 /PRNewswire/ -- Banistmo, S.A. ("Banistmo") announces the expiration and results of its previously announced consent solicitation
More news about: Banistmo, S.A.
Apr 17, 2026, 15:00 ET Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting
selected tumor types. IMT-009 is a fully human, Fc-attenuated IgG1 monoclonal antibody that targets CD161, a receptor associated with immune suppression and treatment resistance in cancer. By blocking the CD161-CLEC2D pathway, IMT-009 is designed to enhance anti-tumor immune activity. In the Phase 1b combination
More news about: Immunitas Therapeutics, Inc.
Apr 17, 2026, 15:00 ET Meiji Holdings Co., Ltd. Highlights that Yogurt Containing Bacteria Metabolite Shows a Tendency Toward Higher Response When Added to Immune Checkpoint Inhibitor Therapy in People Living with Non-small Cell Lung Cancer
blood during immunotherapy – a CD4⁺ T cell subset considered to be linked to better, longer-lasting responses to PD-1 inhibitors such as pembrolizumab.In patients receiving pembrolizumab, yogurt intake was associated with increased cancer-killing GZMB⁺ CD8⁺ T cells, suggesting enhanced
More news about: Meiji Holdings Co Ltd
Apr 17, 2026, 15:00 ET Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application
Dr. David Rimm's lab at Yale University School of MedicineAI-based target discovery for bi-specific antibodiesBiomarker research in CD47-targeted therapies"Our AACR presentations reflect how AI is increasingly translating into real-world clinical impact" said Brandon Suh,
More news about: Lunit
Apr 17, 2026, 09:00 ET Parker Institute for Cancer Immunotherapy Network Shapes the Future Of Immunotherapy with Latest Research at AACR Annual Meeting 2026
Abstract 3444) and spatial remodeling of the tumor microenvironment by IL-18-armored CD19 CAR T cells (
More news about: Parker Institute for Cancer Immunotherapy
Apr 16, 2026, 12:15 ET itel Launches Personalized Training Podcasts - AI-Generated Agent Training
to a 17% increase in productivity and 21% higher profitability. Recognizing these trends, itel's CEO and Founder, Yoni Epstein, CD, states that "we have embedded employee development at the core of itel's business strategy, ensuring that team members are equipped with the skills,
More news about: itel
Apr 16, 2026, 12:15 ET VerifiedX Launches the First Native Bitcoin and VFX Privacy Transactions, Introducing Confidential Financial Infrastructure for Institutions and Everyone
https://discord.gg/7cd5ebDQCj Twitter (X)):
More news about: VerifiedX.io
Apr 16, 2026, 12:15 ET VerifiedX Launches the First Native Bitcoin and VFX Privacy Transactions, Introducing Confidential Financial Infrastructure for Institutions and Everyone
https://discord.gg/7cd5ebDQCj Twitter (X)):
More news about: VerifiedX.io
Apr 16, 2026, 10:34 ET nugs Announces Play Dead, the Official App for Streaming the Grateful Dead Vault in Hi-Res
available on CD.With Play Dead, listeners can experience:Exclusive access to newly transferred, mastered and enhanced recordings from the vault, streaming in hi-resNew vault releases every Tuesday, curated by David Lemieux and mastered by David GlasserCD-only
More news about: nugs